Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas

22 Jul 2015

Abstract excerpt

INTRODUCTION: Thyroid transcription factor 1 (TTF1) is a master regulator of pulmonary differentiation that is downregulated in a subset of lung adenocarcinoma, of which the clinicopathologic characteristics were not fully clarified. METHODS: One thousand forty-two lung adenocarcinoma patients who underwent surgery were investigated for clinic characteristics, histologic subtyping, and spectrum of well-identified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26200450
DOI: 10.1097/jto.0000000000000626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung AdenocarcinomasPMID 26200450Read ↗

Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.Semantic proximity Read ↗

Thyroid transcription factor 1 (TTF-1) negativity as a predictor of unfavorable response to EGFR-TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations.Semantic proximity Read ↗

The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.Semantic proximity Read ↗

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.Semantic proximity Read ↗

Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.Semantic proximity Read ↗

Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung AdenocarcinomaSemantic proximity Read ↗

Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry studySemantic proximity Read ↗

Clinical significance of TTF‐1 protein expression and <i>TTF‐1</i> gene amplification in lung adenocarcinomaSemantic proximity Read ↗

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.Semantic proximity Read ↗

The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinomaSemantic proximity Read ↗

An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.Semantic proximity Read ↗

Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.